Zavegepant clinical trials
Also written BHV3500.
How each study uses zavegepant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zavegepant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 9 Mar 2023 · ZAVZPRET · NDA 216386 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 5
Pfizer (13) · American Center for Psychiatry and Neurology (1) · The University of Texas Health Science Center, Houston (1) · University of South Florida (1) · Mayo Clinic (1) · Icahn School of Medicine at Mount Sinai (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of CGRP receptor antagonists source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test zavegepant.
- Mar 2027Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive MedicationsPhase 4 · Mayo Clinic
- Jul 2027A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency DepartmentPhase 1 · University of South Florida
- Aug 2027A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of MigrainePhase 1 · Pfizer
Studies
Open first, then newest update. How each study uses zavegepant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency DepartmentRecruitingPhase 1University of South FloridaNCT07667621Written as Zavegepant
- A Prospective Interventional Study of Intranasal Zavegepant for the Acute Treatment of MigraineNot yet recruitingNot applicableAmerican Center for Psychiatry and NeurologyNCT07861412Written as intranasal zavegepant
- Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster HeadacheNot yet recruitingPhase 2The University of Texas Health Science Center, HoustonNCT07714369Written as Zavegepant 20 mg
- A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of MigraineRecruitingPhase 1PfizerNCT06995729Written as Zavegepant
- Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive MedicationsRecruitingPhase 4Mayo ClinicNCT06401642Written as Zavegepant
- A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian AdultsCompletedPhase 3PfizerNCT05989048Written as Zavegepant
- Acute Migraine Treatment in the ED With GepantsTerminatedPhase 4Icahn School of Medicine at Mount SinaiNCT06985342Written as Zavegepant
- A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric MicrosamplingCompletedPhase 1PfizerNCT05948085Written as Zavegepant 10 mg IN
- A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult ParticipantsWithdrawnPhase 3PfizerNCT06103734Written as Zavegepant 10 mg
- A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine PreventionTerminatedPhase 2/3PfizerNCT04804033Written as BHV-3500 (zavegepant)
- A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult ParticipantsCompletedPhase 1PfizerNCT05960032Written as Zavegepant
- A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding WomenCompletedPhase 1PfizerNCT06453356Written as Zavegepant 10mg
- A Study to Learn About the Study Medication, Zavegepant, in Healthy VolunteersCompletedPhase 1PfizerNCT06137703Written as Zavegepant 100mg non-enteric coated soft gel capsule
- Safety and Efficacy Active Drug vs. Placebo in Subjects With AsthmaTerminatedPhase 1PfizerNCT04987944Written as Zavegepant
- Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental OxygenTerminatedPhase 2/3PfizerNCT04346615Written as Zavegepant (BHV-3500)
- Acute Treatment Trial in Adult Subjects With MigrainesCompletedPhase 2/3PfizerNCT03872453Written as Zavegepant
- Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of MigraineCompletedPhase 2/3PfizerNCT04408794Written as Zavegepant (BHV-3500)
- Randomized Trial in Adult Participants With Acute MigrainesCompletedPhase 3PfizerNCT04571060Written as Zavegepant
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting1
Codes
What other systems call zavegepant · ClinicalTrials.gg INT006389
- MeSH (NLM) C584752zavegepantOne source NLM
- UNII (FDA) ODU3ZAZ94JZAVEGEPANTConfirmed FDA, NLM, Wikidata
- Wikidata Q99388898zavegepantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C172616ZavegepantOne source FDA
- DrugBank DB15688One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584752 | zavegepant | One source NLM |
| UNII (FDA) | ODU3ZAZ94J | ZAVEGEPANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q99388898 | zavegepant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C172616 | Zavegepant | One source FDA |
| DrugBank | DB15688 | — | One source Wikidata |
Also registered as zavegepant hydrochloride (UNII 000QCM6HAL).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.